Literature DB >> 29511350

TBX3 promotes proliferation of papillary thyroid carcinoma cells through facilitating PRC2-mediated p57KIP2 repression.

Xiaomeng Li1, Xianhui Ruan2, Peitao Zhang1, Yang Yu2, Ming Gao2, Shukai Yuan1, Zewei Zhao1, Jie Yang3, Li Zhao4.   

Abstract

The T-box transcription factor TBX3 has been implicated in the patterning and differentiation of a number of tissues during embryonic development, and is overexpressed in a variety of cancers; however, the precise function of TBX3 in papillary thyroid carcinoma (PTC) development remains to be determined. In the current study, we report downregulation of TBX3 in PTC cells delays the G1/S-phase transition, decreases cell growth in vitro, and inhibits tumor formation in vivo. We identified p57KIP2 as a novel downstream target that serves as the key mediator of TBX3's control over PTC cell proliferation. Reduced expression of TBX3 resulted in increased p57KIP2 level, while knockdown of p57KIP2 rescues the cell-cycle arrest phenotype. In clinical PTC specimens, the expression of TBX3 is markedly upregulated and significantly correlated with advanced tumor grade, but negatively correlated with the expression of p57KIP2. Mechanism investigation revealed that TBX3 directly binds to the CDKN1C gene promoter region, the coding gene of p57KIP2, and represses its transcription. Furthermore, recruitment of main components of the PRC2 complex as well as class I histone deacetylases, HDAC1 and HDAC2, is required for TBX3 to fulfill the transcriptional repression function. Our findings illustrate the previously unknown function and mechanism in cell proliferation regulation by the TBX3-p57KIP2 axis and provide evidence for the contribution of the PRC2 complex and HDAC1/2. Targeting of this pathway may present a novel and molecular defined strategy against PTC development.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29511350     DOI: 10.1038/s41388-017-0090-2

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  38 in total

1.  The T-Box factor TBX3 is important in S-phase and is regulated by c-Myc and cyclin A-CDK2.

Authors:  Tarryn Willmer; Jade Peres; Shaheen Mowla; Amaal Abrahams; Sharon Prince
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

2.  Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling.

Authors:  Christine M Fillmore; Piyush B Gupta; Jenny A Rudnick; Silvia Caballero; Patricia J Keller; Eric S Lander; Charlotte Kuperwasser
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-22       Impact factor: 11.205

Review 3.  p57(Kip2) and cancer: time for a critical appraisal.

Authors:  Adriana Borriello; Ilaria Caldarelli; Debora Bencivenga; Maria Criscuolo; Valeria Cucciolla; Annunziata Tramontano; Adriana Oliva; Silverio Perrotta; Fulvio Della Ragione
Journal:  Mol Cancer Res       Date:  2011-08-04       Impact factor: 5.852

4.  Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling.

Authors:  Norihiro Sato; Hiroyuki Matsubayashi; Tadayoshi Abe; Noriyoshi Fukushima; Michael Goggins
Journal:  Clin Cancer Res       Date:  2005-07-01       Impact factor: 12.531

5.  Overexpression of Tbx3 is correlated with Epithelial-Mesenchymal Transition phenotype and predicts poor prognosis of colorectal cancer.

Authors:  Ze-Zhi Shan; Xue-Bing Yan; Lei-Lei Yan; Yuan Tian; Qing-Cai Meng; Wang-Wang Qiu; Zhen Zhang; Zhi-Ming Jin
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

6.  The T-box repressors TBX2 and TBX3 specifically regulate the tumor suppressor gene p14ARF via a variant T-site in the initiator.

Authors:  Merel E Lingbeek; Jacqueline J L Jacobs; Maarten van Lohuizen
Journal:  J Biol Chem       Date:  2002-05-08       Impact factor: 5.157

7.  Loss of imprinting and genetic alterations of the cyclin-dependent kinase inhibitor p57KIP2 gene in head and neck squamous cell carcinoma.

Authors:  S Lai; H Goepfert; A M Gillenwater; M A Luna; A K El-Naggar
Journal:  Clin Cancer Res       Date:  2000-08       Impact factor: 12.531

8.  Expression of the components of the Cip/Kip family in malignant lymphoma of the thyroid.

Authors:  Yasuhiro Ito; Hiroshi Yoshida; Fumio Matsuzuka; Nariaki Matsuura; Yasushi Nakamura; Hirokazu Nakamine; Kennichi Kakudo; Kanji Kuma; Akira Miyauchi
Journal:  Pathobiology       Date:  2004       Impact factor: 4.342

9.  Disruption of SoxB1-dependent Sonic hedgehog expression in the hypothalamus causes septo-optic dysplasia.

Authors:  Li Zhao; Solsire E Zevallos; Karine Rizzoti; Yongsu Jeong; Robin Lovell-Badge; Douglas J Epstein
Journal:  Dev Cell       Date:  2012-03-13       Impact factor: 12.270

10.  TBX3, the gene mutated in ulnar-mammary syndrome, promotes growth of mammary epithelial cells via repression of p19ARF, independently of p53.

Authors:  Natalia Platonova; Maddalena Scotti; Polina Babich; Gloria Bertoli; Elena Mento; Vasco Meneghini; Aliana Egeo; Ileana Zucchi; Giorgio R Merlo
Journal:  Cell Tissue Res       Date:  2007-01-30       Impact factor: 5.249

View more
  12 in total

1.  Identification of gene co-expression modules and hub genes associated with lymph node metastasis of papillary thyroid cancer.

Authors:  Tianyu Zhai; Dilidaer Muhanhali; Xi Jia; Zhiyong Wu; Zhenqin Cai; Yan Ling
Journal:  Endocrine       Date:  2019-07-22       Impact factor: 3.633

Review 2.  The roles and regulation of TBX3 in development and disease.

Authors:  Saif F Khan; Victoria Damerell; Rehana Omar; Michelle Du Toit; Mohsin Khan; Hapiloe Mabaruti Maranyane; Mihlali Mlaza; Jenna Bleloch; Claire Bellis; Bianca D B Sahm; Jade Peres; K N ArulJothi; Sharon Prince
Journal:  Gene       Date:  2019-10-26       Impact factor: 3.688

3.  GATA binding protein 1 recruits histone deacetylase 2 to the promoter region of nuclear receptor binding protein 2 to affect the tumor microenvironment and malignancy of thyroid carcinoma.

Authors:  Mengyuan Li; Hongwei Jiang; Shengjiang Chen; Yujin Ma
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

4.  LncRNA LUCAT1 as a novel prognostic biomarker for patients with papillary thyroid cancer.

Authors:  B Luzón-Toro; R M Fernández; J M Martos-Martínez; M Rubio-Manzanares-Dorado; G Antiñolo; S Borrego
Journal:  Sci Rep       Date:  2019-10-07       Impact factor: 4.379

5.  CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27 trimethylation at the CDKN1C promoter.

Authors:  Zhengang Qiu; Weiliang Zhu; Hui Meng; Lihua Tong; Xi Li; Peng Luo; Lilan Yi; Xiaoli Zhang; Linlang Guo; Ting Wei; Jian Zhang
Journal:  Theranostics       Date:  2019-07-09       Impact factor: 11.556

6.  Oncoprotein HBXIP promotes tumorigenesis through MAPK/ERK pathway activation in non-small cell lung cancer.

Authors:  Jun Zhang; Bei Sun; Xianhui Ruan; Xiukun Hou; Jingtai Zhi; Xiangrui Meng; Xiangqian Zheng; Ming Gao
Journal:  Cancer Biol Med       Date:  2021-02-15       Impact factor: 4.248

7.  Potential Novel Modules and Hub Genes as Prognostic Candidates of Thyroid Cancer by Weighted Gene Co-Expression Network Analysis.

Authors:  Zhiqiang Shi; Xinghui Li; Long Zhang; Yilang Luo; Bikal Shrestha; Xuegang Hu
Journal:  Int J Gen Med       Date:  2021-12-07

8.  Establishment of the TBX-code reveals aberrantly activated T-box gene TBX3 in Hodgkin lymphoma.

Authors:  Stefan Nagel; Corinna Meyer
Journal:  PLoS One       Date:  2021-11-22       Impact factor: 3.240

Review 9.  Genetic and Epigenetic Control of CDKN1C Expression: Importance in Cell Commitment and Differentiation, Tissue Homeostasis and Human Diseases.

Authors:  Emanuela Stampone; Ilaria Caldarelli; Alberto Zullo; Debora Bencivenga; Francesco Paolo Mancini; Fulvio Della Ragione; Adriana Borriello
Journal:  Int J Mol Sci       Date:  2018-04-02       Impact factor: 5.923

10.  TBX3 knockdown suppresses the proliferation of hypopharyngeal carcinoma FaDu cells by inducing G1/S cell cycle arrest and apoptosis.

Authors:  Yongjiu Huang; Hongmei Zhu; Xiaohui Ji; Yin Chen; Yanhui Zhang; Ruofei Huang; Jin Xie; Pin Dong
Journal:  Oncol Lett       Date:  2019-11-13       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.